Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques

Molecular Brain Research

Volumn 53, Issue 1-2, 1998, Pages 120-129

  Pecins Thompson, Melanie ^a   A Brown, Nancy ^a   Bethea, Cynthia L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dorsal raphe; Estrogen; Primate; Progesterone; Serotonin; SERT

Indexed keywords

COMPLEMENTARY RNA; ESTROGEN; MESSENGER RNA; PROGESTERONE; PROLACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; FEMALE; HYSTERECTOMY; IN SITU HYBRIDIZATION; MEDIAN RAPHE NUCLEUS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROLACTIN RELEASE; RHESUS MONKEY; RNA PROBE; SEROTONINERGIC NERVE CELL;

ANIMALS; CARRIER PROTEINS; DRUG IMPLANTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYSTERECTOMY; IN SITU HYBRIDIZATION; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; OVARIECTOMY; PROGESTERONE; RAPHE NUCLEI; RNA, MESSENGER; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSCRIPTION, GENETIC;

ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 0031932036     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(97)00286-6     Document Type: Article

References (62)

1. Albinsson A., Palazidou E., Stephenson J., Andersson G. Involvement of the 5HT2 receptor in the 5HT receptor-mediated stimulation of prolactin release. Eur. J. Pharmacol. 251:1994;157-161.
2. Anderson I.M., Ware C.J., Da Roza Davis J.M., Cowen P.J. Decreased 5-HT-mediated prolactin release in major depression. Br. J. Psychiatry. 160:1992;372-378.
3. E.L. Barker, R.D. Blakely, Norepinephrine and serotonin transporters. Molecular targets of antidepressant drugs, in: F.E. Bloom, D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, 1995, pp. 321-333.
4. Bethea C.L. Regulation of progestin receptors in raphe neurons of steroid-treated monkeys. Neuroendocrinology. 60:1994;50-61.
5. Bethea C.L., Brown N.A., Kohama S.G. Steroid regulation of estrogen and progestin receptor messenger ribonucleic acid in monkey hypothalamus and pituitary. Endocrinology. 137:1996;4372-4383.
6. Bethea C.L., Fahrenbach W.H., Sprangers S.A., Freesh F. Immunocytochemical localization of progestin receptors in monkey hypothalamus: effect of estrogen and progestin. Endocrinology. 130:1992;895-905.
7. Blakely R.D., De Felice L.J., Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J. Exp. Biol. 196:1994;236-281.
8. Blaustein J.D., Turcotte J.C. Estradiol-induced progestin receptor immunoreactivity is found only in estrogen receptor-immunoreactive cells in guinea pig brain. Neuroendocrinology. 49:1989;454-461.
9. Brenner R.M., West N.B. Hormonal regulation of the reproductive tract in female mammals. Annu. Rev. Physiol. 37:1975;273.
10. Clarke C.L. Cell-specific regulation of progesterone receptor in the female reproductive system. Mol. Cell. Endocrinol. 70:1990;C29-C33.
11. J.A. Clemens, Neuropharmacological aspects of the neural control of prolactin secretion, in: F. Labrie, J. Meites, G. Pelletier (Eds.), Hypothalamus and Endocrine Functions, Plenum, New York, 1975, pp. 283-301.
12. de Lignieres B., Vincens M. Differential effects of exogenous oestradiol and progesterone on mood in post-menopausal women: individual dose/effect relationship. Maturitas. 4:1982;67-72.
13. Eriksson E., Hedberg M.A., Andersch B., Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 12:1995;167-176.
14. Flores C.M., Hulihan-Giblin B.A., Hornby P.J., Lumpkin M.D., Kellar K.J. Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin. Neuroendocrinology. 55:1992;519-528.
15. Fumagalli F., Jones S.R., Caron M.G., Seidler F.J., Slotkin T.A. Expression of mRNA coding for the serotonin transporter in aged vs. young rat brain: differential effects of glucocorticoids. Brain Res. 719:1996;225-228.
16. Gilardi K.V.K., Shideler S.E., Valverde C.R., Roberts J.A., Lasley B.L. Characterization of the onset of menopause in the rhesus macaque. Biol. Reprod. 57:1997;335-340.
17. Gitlin M.J., Pasnau R.O. Psychiatric syndromes linked to reproductive function in women: a review of current knowledge. Am. J. Psychiat. 146:1989;1413-1422.
18. G.L. Greene, V. Sharma, L. Cheng, Estrogen receptor structure and function in breast cancer cells, in: J.G. Fortner, P.A. Sharp (Eds.), General Motors Accomplishments in Cancer Research, Lippincott, Philadelphia, PA, 1996, pp. 147-156.
19. Gregoire A.J.P., Kumar R., Everitt B., Henderson A.F., Studd J.W.W. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 347:1996;930-933.
20. Halbreich U., Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int. J. Psychiat. Med. 23(1):1993;1-27.
21. G. Halliday, A. Harding, G. Paxinos, Serotonin and tachykinin systems, in: G. Paxinos (Ed.), The Rat Nervous System, Academic Press, New York, 1995, pp. 929-974.
22. Heils A., Teufel A., Petri S., Seemann M., Bengel D., Balling U., Riederer P., Lesch K.P. Functional promoter and polyadenylation site mapping of the human serotonin (5HT) transporter gene. J. Neural. Transm. 102:1995;247-254.
23. B.J. Hoffman, K.J. Miller, L.M. Gould, New perspectives on signal transmission: the serotonin transporter, Program of the Third IUPHAR Satellite Meeting on Serotonin, Chicago, IL, (1994) Symposium #4, p. 10.
24. J. Hotchkiss, K. Knobil, The menstrual cycle and its neuroendocrine control, in: E. Knobil, J.D. Neill (Eds.), The Physiology of Reproduction, Raven Press, New York, 1994, pp. 711-750.
25. Jahn G.A., Deis R.P. A possible dual regulation of prolactin release by the sertoninergic system in rats at pro-oestrus and during late pregnancy. J. Endocrinol. 112:1987;367-374.
26. Jorgensen H., Knigge U., Warber J. Involvement of 5HT1, 5HT2, and 5HT3 receptors in the mediation of the prolactin response to 5-hydroxytryptophan. Neuroendocrinology. 55:1992;336-343.
27. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 10:1996;119-131.
28. C. Kordon, S.V. Drouva, G. Martinez de L.Escaler, R.I. Weiner, Role of classic and peptide neuromediators in the neuroendocrine regulation of luteinizing hormone and prolactin, in: E. Knobil, J.D. Neill (Eds.), The Physiology of Reproduction, Raven Press, New York, 1994, pp. 1621-1681.
29. Maes M., D'Hondt P.D., Suy E., Minner B., Vandervorst C., Raus J. HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. Prog. Neuropsychopharmacol. Biol. Psychiat. 15:1991;781-790.
30. Maes M., Vandewoude M., Schotte C., Maes L., Martin M., Blockx P. Sex-linked differences in cortisol, ACTH and prolactin responses to 5-hydroxy-tryptophan in healthy controls and minor and major depressed patients. Acta Psychiat. Scand. 80:1989;584-590.
31. Majewska M.D. Neurosteroids: endogenous bimodal modulators of the GABA-A receptor. Mechanism of action and physiological significance. Prog. Neurobiol. 38:1992;379-395.
32. Mathiasen J.R., Tomogane H., Voogt J.L. Serotonin-induced decrease in hypothalamic tyrosine hydroxylase activity and corresponding increase in prolactin release are abolished at midpregnancy and by transplants of rat choriocarcinoma cells. Endocrinology. 131:1992;2527-2532.
33. McQueen J.K., Wilson H., Fink G. Estgradiol-17β increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Mol. Brain Res. 45:1997;13-23.
34. Meister B., Johnson H., Ulfhake B. Increased expression of serotonin transporter messenger RNA in raphe neurons of the aged rat. Mol. Brain Res. 33:1995;87-96.
35. 3H]-paroxitine binding in the cerebral cortex and dorsal hippocampus of gonadectomized male and female rats. Brain Res. 601:1993;299-302.
36. Mistry A.M., Voogt J.L. Serotonin synthesis inhibition or receptor antagonism reduces pregnancy-induced nocturnal prolactin secretion. Life Sci. 47:1990;693-701.
37. Mortola J.F. A risk-benefit appraisal of drugs used in the management of premenstrual syndrome. Drug Safety. 10:1994;160-169.
38. Oppenheim G. Estrogen in the treatment of depression: neuropharmacological mechanisms. Biol. Psychiat. 18:1983;721-725.
39. Parry B.L. Psychobiology of premenstrual dysphoric disorder. Semin. Reprod. Endocrinol. 15:1997;55-68.
40. S.M. Paul, M. Rehavi, P. Skolnick, et al., High affinity binding of antidepressants to biogenic amine transport sites in human brain and platelet: studies in depression, in: R.M. Post, J.C. Ballenger (Eds.), Neurobiology of Mood Disorders, Williams and Wilkins, Baltimore, MD, 1984, pp. 846-853.
41. Pecins-Thompson M., Bethea C.L. RU 486 blocks and fluoxetine augments progesterone-induced prolactin secretion in monkeys. Neuroendocrinology. 65:1997;335-343.
42. Pecins-Thompson M., Brown N.A., Kohama S.G., Bethea C.L. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J. Neurosci. 16:1996;7021-7029.
43. Ramamoorthy S., Aauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., Ganapathy V., Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. PNAS. 90:1993;2542-2546.
44. Rehavi M., Sepcuti H., Weizman A. Upregulation of imipramine binding and serotonin uptake by estradiol in female rat brain. Brain Res. 410:1987;135-139.
45. Ribeiro R.C., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Ann. Rev. Med. 46:1995;443-453.
46. L.S. Schneider, G.W. Small, S.H. Hamilton, A. Bystritsky, C.B. Nemeroff, B.S. Meyers, Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial, Am. J. Geriat. Psychol., 5 (1997) 97-106.
47. Sherwin B.B. The psychoendocrinology of aging and female sexuality. Ann. Rev. Sex Res. 2:1991;181-198.
48. B.B. Sherwin, Menopause, early aging and elderly women, in: M.F. Jensvold, U. Halbreich, J.A. Hamiltion (Eds.), Psychopharmacology and Women: Sex, Gender and Hormones, American Psychiatric Press, Washington, DC, 1996, pp. 225-240.
49. Sherwin B.B., Suranyi-Cadotte B.E. Up-regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopausal women. Biol. Psychiat. 28:1990;339-348.
50. Siever L.J., Kahn R.S., Lawlor B.A., Trestman R.L., Lawrence T.L., Coccaro E.F. II Critical issues in defining the role of serotonin in psychiatric disorders. Pharmacol. Rev. 43:1991;509-525.
51. Sprangers S.A., Brenner R.M., Bethea C.L. Estrogen and progestin receptor immunocytochemistry in lactotropes versus gonadotropes of monkey pituitary cell cultures. Endocrinology. 124:1989;1462-1470.
52. Sprangers S.A., West N.B., Brenner R.M., Bethea C.L. Regulation and localization of estrogen and progestin receptors in the pituitary of steroid treated monkeys. Endocrinology. 126:1990;1133-1142.
53. Steiner M., Steinber S., Stewart D., Carter D., Berger C., Reid R., Grover D., Streiner D. Fluoxetine in the treatment of premenstrual dysphoria. N. Engl. J. Med. 332:1995;1529-1534.
54. Su T.P., Schmidt P.J., Danaceau M., Murphy D.L., Rubinow D.R. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J. Clin. Endocrinol. Metab. 82:1997;1220-1228.
55. I. Tork, J.-P. Hornung, Raphe nuclei and the serotonergic system, in: G. Paxinos (Ed.), The Human Nervous System, Academic Press, New York, 1990, pp. 1001-1022.
56. Van de Kar L.D. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Ann. Rev. Pharmacol. Toxicol. 31:1991;289-320.
57. Van de Kar L.D., Bethea C.L. Pharmacological evidence that serotonergic stimulation of prolactin secretion is mediated via the dorsal raphe nucleus. Neuroendocrinology. 35:1982;225-230.
58. Van de Kar L.D., Carnes M., Maslowski J., Bonadonna A.M., Rittenhouse P.A., Kunimoto K., Piechowski R.A., Bethea C.L. Neuroendocrine evidence for denervation supersensitivity of serotonin receptors: effects of the 5HT agonist RU 24969 on corticotropin, corticosterone, prolactin and renin secretion. J. Pharm. Exp. Ther. 251:1989;428-433.
59. Webb P., Lopez G.N., Uht P.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/Ap-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9:1995;443-456.
60. Weissman M.M., Klerman G.L. Gender and depression. Trends Neurosci. 8:1985;416-420.
61. Williams R.F., Gianfortoni J.G., Hodgen G.D. Hyperprolactinemia induced by an estrogen-progesterone synergy: quantitative and temporal effects of estrogen priming in monkeys. J. Clin. Endocrinol. Metab. 60:1985;126-132.
62. P.M. Yen, Dominant negative activity by estrogen and progesterone receptors, in: E.J. Pavlik (Ed.), Estrogens, Progestins and Their Antagonists, Vol. 2, Birkhauser, Boston, MA, 1996, pp. 153-168.